Mereo BioPharma Group PLC ADR (MREO)

Currency in USD
0.2600
-0.0150(-5.45%)
Closed·
0.26000.0000(0.00%)
·
MREO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.26000.2774
52 wk Range
0.20002.3700
Key Statistics
Prev. Close
0.26
Open
0.2752
Day's Range
0.26-0.2774
52 wk Range
0.2-2.37
Volume
1.09M
Average Volume (3m)
1.23M
1-Year Change
-85.5556%
Book Value / Share
0.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MREO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.9403
Upside
+646.28%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
2 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1.9403
(+646.28% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Buy3.00+1,053.85%-MaintainSep 18, 2026
JPMorgan
Sell---DowngradeAug 18, 2026
Baird
Buy1.00+284.62%-MaintainMar 24, 2026
JPMorgan
Hold---DowngradeMar 23, 2026
BTIG
Buy1.00+284.62%-MaintainMar 19, 2026

Mereo BioPharma Group PLC ADR SWOT Analysis


Pipeline Promise
Explore Mereo BioPharma's late-stage assets: setrusumab for osteogenesis imperfecta and alvelestat for AATD, poised to transform rare disease treatment
Market Potential
Delve into setrusumab's commercial prospects, with EU revenue potentially exceeding $500M by mid-2030s and a lean sales force requirement
Financial Health
Learn about Mereo's strong cash position, supporting operations into 2027, and its attractive valuation relative to perceived opportunity
Analyst Outlook
Discover Wall Street's optimism with price targets ranging from $6.41 to $10.68, significantly above the current $2.53 share price
Read full SWOT analysis

Earnings

Latest Release
Nov 09, 2026
EPS / Forecast
-0.01 / -0.02
Revenue / Forecast
800K / --
EPS Revisions
Last 90 days

MREO Income Statement

Compare MREO to Peers and Sector

Metrics to compare
MREO
Peers
Sector
Relationship
P/E Ratio
−1.5x−1.4x−0.2x
PEG Ratio
−0.050.220.00
Price/Book
1.8x6.0x2.6x
Price / LTM Sales
51.9x3.1x2.6x
Upside (Analyst Target)
-154.3%76.9%
Fair Value Upside
Unlock28.7%14.9%Unlock

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
264.50K0.17%68.77K
Other Institutional Investors
171.86M99.83%44.68M
Public Companies & Retail Investors
0.000.00%0.00
Total
172.12M100.00%44.75M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
EcoR1 Capital Fund Qualified, L.P.47.07%75,173,53219,545
Rubric Capital Management LP13.59%21,697,3475,641

People Also Watch

390.94
ONC
-2.19%
16.48
RARE
-4.30%
56.46
BRKR
-9.08%
5.570
OCUL
-4.95%

FAQ

What Is the Mereo BioPharma ADR (MREO) Stock Price Today?

The Mereo BioPharma ADR stock price today is 0.2600 USD.

What Stock Exchange Does Mereo BioPharma ADR Trade On?

Mereo BioPharma ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Mereo BioPharma ADR?

The stock symbol for Mereo BioPharma ADR is "MREO."

What Is the Mereo BioPharma ADR Market Cap?

As of today, Mereo BioPharma ADR market cap is 43.9200M USD.

What Is Mereo BioPharma ADR's Earnings Per Share (TTM)?

The Mereo BioPharma ADR EPS (TTM) is -0.17.

When Is the Next Mereo BioPharma ADR Earnings Date?

Mereo BioPharma ADR will release its next earnings report on Mar 31, 2027.

From a Technical Analysis Perspective, Is MREO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Mereo BioPharma ADR Stock Split?

Mereo BioPharma ADR has split 0 times.

How Many Employees Does Mereo BioPharma ADR Have?

Mereo BioPharma ADR has 39 employees.

What is the current trading status of Mereo BioPharma ADR (MREO)?

As of Nov 21, 2026, Mereo BioPharma ADR (MREO) is trading at a price of 0.2600 USD, with a previous close of 0.2600 USD. The stock has fluctuated within a day range of 0.2600 USD to 0.2774 USD, while its 52-week range spans from 0.2000 USD to 2.3700 USD.

What Is Mereo BioPharma ADR (MREO) Price Target According to Analysts?

The average 12-month price target for Mereo BioPharma ADR is 1.9403 USD, with a high estimate of 2.92631854 USD and a low estimate of 0.97500327 USD. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +646.28% Upside potential.

What Is the MREO Premarket Price?

MREO's last pre-market stock price is 0.2751 USD. The pre-market share volume is 390.0000, and the stock has decreased by 0.0001, or 0.0400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.